Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Blood Cancer Journal|April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosisSurbhi Sidana, Paolo Milani, Moritz Binder, et al.Journal of the American Heart Association|December 24, 2024
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, et al.JACC. Cardiooncology|September 12, 2025
Diagnostic Performance of the New Free Light Chain Ratio in Systemic AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Claudia Bellofiore, et al.Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.Blood Cancer Journal|February 17, 2021
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosisGiovanni Palladini, Bruno Paiva, Ashutosh Wechalekar, et al.Leukemia|May 24, 2022
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosisAlice Nevone, Maria Girelli, Silvia Mangiacavalli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain AmyloidosisEfstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.European Journal of Heart Failure|March 12, 2023
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network studyGiacomo Tini, Paolo Milani, Mattia Zampieri, et al.Journal of Cardiovascular Medicine (Hagerstown, Md.)|February 17, 2026
Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-studyLaura De Michieli, Giacomo Tini, Alessia Argirò, et al.Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 26, 2025
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosisAlberto Aimo, Paolo Milani, Giacomo Tini, et al.Pageof 7